RADX Nasdaq Pharmaceutical Preparations Financials FY2023βFY2026
Radiopharm Theranostics Ltd had $2.8M of revenue in fiscal 2026, down 23.8% on the year before.
Hi! I read Radiopharm Theranostics Ltdβs latest annual report (fiscal 2026). Here is what stands out:
Good So-so Weak
Are sales growing?
β23.8%
No. Sales fell 23.8% last year.
Does it make a profit?
β2,057.5%
No. It lost money last year.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Radiopharm Theranostics Ltd did it, and the next one. Share prices often move a lot on those days.
Next results
September 29, 2027
Wednesday Β· in 338 days
Estimated from the same quarter last year. It will be replaced by the announced date once there is one.
See who else reports that week βKIRA Β· Radiopharm Theranostics Ltd had $2.8M of revenue in fiscal 2026, down 23.8% on the year before. Its operating margin was β2,051.5%, down 1,000.9Β pts: of every 100 in sales, about β2,052 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Margins, % of revenue
KIRA Β· Radiopharm Theranostics Ltd lost $57.0M in fiscal 2026.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Diluted EPS
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Radiopharm Theranostics Ltd can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Cash and short-term investments | $11.7M | $18.6M | $29.1M | $4.1M |
| Interest coverage | β400.5x | β73.4x | β584.6x | β505.2x |
| Current ratio | β | 1.3x | 2.7x | 1.2x |
| Quick ratio | β | 1.3x | 2.7x | 1.2x |
| Total assets | β | $72.0M | $86.5M | $60.1M |
| Total liabilities | β | $44.7M | $43.6M | $37.8M |
| Shareholders' equity | $45.6M | $27.4M | $42.9M | $22.3M |
| Net debt (β = net cash) | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Radiopharm Theranostics Ltd passes 3 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Net income is positive | β | β | β | β |
| Cash from operations is positive | β | β | β | β |
| Return on assets rose | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β |
| Debt fell relative to assets | β | β | β | β |
| Current ratio rose | β | β | β | β |
| Share count didn't rise | β | β | β | β |
| Gross margin rose | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β |
| F-score | β / 3 | β / 5 | 4 / 8 | 3 / 8 |
| Accruals ratio | β | β34.7% | β2.1% | β5.7% |
| Altman Z'' | β | β | β | β |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.3M | $0.3M | $3.6M | $2.8M |
| Gross profit | $0.3M | $0.3M | $0.0M | $0.3M |
| Research and development | $22.6M | $23.1M | $27.5M | $50.0M |
| Operating income | β$34.5M | β$47.2M | β$38.2M | β$56.8M |
| Interest expense | $0.1M | $0.6M | $0.1M | $0.1M |
| Pretax income | β$34.6M | β$47.9M | β$38.2M | β$56.9M |
| Income tax | $0.0M | $0.1M | $0.1M | $0.1M |
| Net income | β$34.6M | β$47.9M | β$38.3M | β$57.0M |
| Diluted EPS | β$3,396.00 | β$3,723.00 | β$528.00 | β$537.00 |
| Diluted shares | 0.00B | 0.00B | 0.01B | 0.01B |
| Cash flow | ||||
| Cash from operations | β$23.2M | β$23.0M | β$36.6M | β$52.8M |
| Capital expenditure | $0.0M | β | β | β |
| Free cash flow | β$23.2M | β | β | β |
| Depreciation and amortization | $3.3M | $3.1M | $2.6M | $2.7M |
| Stock-based compensation | $3.0M | $2.6M | $1.9M | $2.4M |
| Balance sheet | ||||
| Cash and short-term investments | $11.7M | $18.6M | $29.1M | $4.1M |
| Current assets | β | $22.8M | $39.9M | $21.9M |
| Current liabilities | β | $17.6M | $14.9M | $18.9M |
| Property and equipment, net | β | $0.1M | $0.1M | $0.0M |
| Intangible assets | $58.5M | $49.1M | $46.6M | $38.2M |
| Total assets | β | $72.0M | $86.5M | $60.1M |
| Total liabilities | β | $44.7M | $43.6M | $37.8M |
| Shareholders' equity | $45.6M | $27.4M | $42.9M | $22.3M |
| Margins | ||||
| Gross margin | 100.0% | 100.0% | 1.1% | 9.5% |
| Operating margin | β11,794.5% | β15,778.7% | β1,050.6% | β2,051.5% |
| EBITDA margin | β10,667.1% | β14,733.8% | β979.2% | β1,953.7% |
| Net margin | β11,836.9% | β16,025.8% | β1,055.3% | β2,057.5% |
| FCF margin | β7,950.4% | β | β | β |
| Returns | ||||
| Return on capital employed | β | β86.7% | β53.4% | β137.7% |
| Return on equity | β75.9% | β131.5% | β109.2% | β174.7% |
| Return on assets | β | β66.6% | β48.4% | β77.7% |
| Growth | ||||
| Revenue growth | β | 2.3% | 1,114.4% | β23.8% |
| Share count change | β | 26.4% | 438.5% | 47.7% |
| Financial health | ||||
| Interest coverage | β400.5x | β73.4x | β584.6x | β505.2x |
| Current ratio | β | 1.3x | 2.7x | 1.2x |
| Quick ratio | β | 1.3x | 2.7x | 1.2x |
| Capital allocation | ||||
| Capex / revenue | 15.5% | β | β | β |
| Stock comp / revenue | 1,039.0% | 882.4% | 52.2% | 86.9% |
| Quality scores | ||||
| Piotroski F-score | β | β | 4.0 | 3.0 |
| Accruals ratio | β | β34.7% | β2.1% | β5.7% |
Source: SEC EDGAR XBRL filings (CIK 0001949257). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Per-share figures are per US-listed share (1 ADS = 300 ordinary shares). For information only β not investment advice. Check the original filings before relying on any figure.
